Genscript Biotech (HK:1548)
:1548
Want to see HK:1548 full AI Analyst Report?
1548 Stock Chart & Stats
HK$13.76
-HK$0.07(-0.74%)
At close: 4:00 PM EST
HK$13.76
-HK$0.07(-0.74%)
Day’s Range― - ―
52-Week RangeHK$9.95 - HK$19.40
Previous CloseN/A
Volume5.33M
Average Volume (3M)11.61M
Market Cap
HK$30.15B
Enterprise ValueHK$4.15B
Total Cash (Recent Filing)HK$843.01M
Total Debt (Recent Filing)HK$523.15M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 19, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding2,188,046,400
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.42Price Target Upside26.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$805.93M
Bulls Say, Bears Say
Bulls Say
Revenue And Margin RecoveryA 74% revenue rebound in 2025 combined with high gross (~57.7%) and stronger EBIT margins indicates the core services and product mix can scale profitably. Durable margins in a services-led model imply pricing power and operational leverage that support sustainable operating performance over months.
Return To Positive Cash GenerationA return to sizable operating and free cash flow provides durable internal funding for capex, working capital and strategic investments. Strong near-term cash generation reduces reliance on external financing and supports execution of longer-term CDMO and research services expansion plans.
Manageable Leverage / Ample Equity BaseLow and improving leverage gives the company financial flexibility to invest in capacity and absorb cyclical revenue swings. A conservative balance sheet supports long-term contract performance, potential capacity buildouts for biologics/CDMO work, and lowers refinancing risk.
Bears Say
Highly Volatile Net IncomeLarge year-to-year swings in net income undermine earnings predictability and complicate capital allocation. Volatility suggests results are influenced by non-recurring items, tax/one-offs or timing effects, limiting confidence that operating improvements will produce stable reported profits over coming quarters.
Inconsistent Historical Cash-flow Track RecordA history of prior cash burn, despite 2025 improvement, raises doubt on durability of free cash flow across cycles. If customer projects slow or working capital needs rise, the company may again face cash pressure and need external funding, hampering long-term investment plans.
Revenue Tied To Customer R&D Cycles And Program ProgressionBusiness relies on project-based contracts and customers' clinical/program milestones, making revenue lumpy and cyclical. Dependence on external R&D budgets and program success reduces visibility into multi-quarter revenue and can lead to under- or over-utilized capacity in the biologics and cell/gene therapy services.
Genscript Biotech News
1548 FAQ
What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$9.95 and its highest was HK$19.40 in the past 12 months.
What is Genscript Biotech’s market cap?
Genscript Biotech’s market cap is HK$30.15B.
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 113 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Mar 16, 2026. The company reported -HK$1.802 earnings per share for the quarter, missing the consensus estimate of -HK$0.235 by -HK$1.567.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Undervalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a Notavailable dividend of HK$0.012 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is -0.08.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,188,046,400 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -HK$1.802 in its last earnings report, missing expectations of -HK$0.235. Following the earnings report the stock price went up 1.262%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in HK:1548
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genscript Biotech Stock Smart Score
Company Description
Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
1548 Company Deck
1548 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.View all HK:1548 earnings summaries1548 Stock 12 Month Forecast
Average Price Target
HK$17.42
▲(26.56% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---